-- 威瑞森通信公司 (Verizon Communications，股票代码：VZ) 周一上调了全年盈利预期，并公布了第一季度业绩，高于市场预期。与此同时，这家电信巨头在第一季度意外增加了后付费电话用户。 该公司目前预计，2026 年调整后每股收益将在 4.95 美元至 4.99 美元之间，高于此前预测的 4.90 美元至 4.95 美元，年增长率为 5% 至 6%。FactSet 目前对该公司非 GAAP 每股收益的普遍预期为 4.90 美元。该股在最近的盘前交易中上涨了 3.9%。 上周，竞争对手 AT&T (股票代码：T) 维持了全年盈利预期，并公布了优于预期的第一季度业绩。 截至 3 月底的第一季度，威瑞森调整后每股收益从上年同期的 1.19 美元增至 1.28 美元，高于华尔街预期的 1.21 美元。营业收入增长2.9%至344.4亿美元，但低于分析师平均预期的348.2亿美元。 该公司本季度新增5.5万零售后付费手机用户，而去年同期则减少了28.9万。FactSet网站上八位分析师的平均预期为减少8.81万用户。 首席执行官丹·舒尔曼在一份声明中表示：“我们2026年第一季度的业绩表明，我们的转型不仅在推进，而且势头强劲。这种稳健的策略已经带来了更健康的经济效益、更低的客户流失率，以及十多年来首次在第一季度实现后付费手机用户净增长。” 据该公司称，移动和宽带服务收入增长1.6%至约229亿美元，其中包括1月份因网络中断导致的无线服务收入增长80个基点的负面影响。服务及其他收入从2025年同期的280.9亿美元小幅增长至287.6亿美元。根据一份演示文稿，宽带净新增用户总数为34.1万，低于去年的35.3万。 2026年，零售后付费电话净新增用户预计将达到Verizon此前发布的75万至100万用户预期范围的上半部分。 该公司继续预计，随着向可持续的基于用户数量的增长模式转型，今年无线服务收入增长将基本持平。该公司还重申了其对移动和宽带服务收入增长2%至3%的预测。
Related Articles
Equities
Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank
Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.
$$CXY
Australia
Cinemark Likely to Benefit From Release Slate, Wedbush Says
Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%
$CNK
Asia Markets
Swiss Market Index Closes Little Changed; Santhera Shares Jump
The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.
$^SSMI$LONN.SW$SANN.SW